Jae Lyun Lee

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

J. Burke, T. Powles, T. Choueiri, 2021, The New England journal of medicine.

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.

T. H. Klotz, S. Culine, J. Hainsworth, 2022, The Lancet. Oncology.

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

S. Culine, M. Climent, T. Choueiri, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Fernando Maciel Barbosa, Raymond J. McDermott, J. Burke, 2022, The Lancet. Oncology.

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.

M. Climent, L. Lacombe, Chung-Han Lee, 2023, The Lancet. Oncology.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

A. Poprach, G. De Velasco, L. Albiges, 2024, The New England journal of medicine.